The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.
Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL.
Mol Cancer Res. 2023 03 01. 21(3):253-260. PMID: 36511902
Research Scientists
Svitlana Tyekucheva
Links
Bibliography
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kd inhibitors.
Gadi D, Martindale SP, Chiu PY, Khalsa J, Chen PH, Fernandes SM, Wang Z, Tyekucheva S, Machado JH, Fisher DC, Armand P, Davids MS, Rodig S, Sherry B, Brown JR.
Blood Cancer J. 2023 02 02. 13(1):22. PMID: 36732326
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS.
Leukemia. 2023 Jan 30. PMID: 36717653
curatedPCaData: Integration of clinical, genomic, and signature features in a curated and harmonized prostate cancer data resource.
Laajala TD, Sreekanth V, Soupir A, Creed J, Calboli FC, Singaravelu K, Orman M, Colin-Leitzinger C, Gerke T, Fidley BL, Tyekucheva S, Costello JC.
bioRxiv. 2023 Jan 19. PMID: 36711769
Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?
Zhou CD, Pettersson A, Plym A, Tyekucheva S, Penney KL, Sesso HD, Kantoff PW, Mucci LA, Stopsack KH.
Cancer Prev Res (Phila). 2022 12 01. 15(12):815-825. PMID: 36125434
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
Lampson BL, Gupta A, Tyekucheva S, Mashima K, Petrácková A, Wang Z, Wojciechowska N, Shaughnessy CJ, Baker PO, Fernandes SM, Shupe S, Machado JH, Fardoun R, Kim AS, Brown JR.
J Clin Oncol. 2023 Feb 10. 41(5):1116-1128. PMID: 36315919
Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance.
Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale SP, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR.
Blood Adv. 2022 Oct 26. PMID: 36287227
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM.
JAMA Oncol. 2022 08 01. 8(8):1177-1183. PMID: 35737367
Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
Gadi D, Griffith A, Wang Z, Tyekucheva S, Rai V, Fernandes SM, Machado JH, Munugalavadla V, Lederer J, Brown JR.
Br J Haematol. 2022 04. 197(2):207-211. PMID: 35170759
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM.
Eur J Cancer. 2022 03. 164:39-51. PMID: 35172272